Review of testicular cancer from 2000 until 2015 in HUSM by Harun, Ahmad Khairul Irham
REVIEW OF TESTICULAR CANCER FROM 
2000 UNTIL 2015 IN HUSM 
 
 
DR AHMAD KHAIRIL IRHAM BIN HARUN 
 
 
Dissertation Submitted in Partial Fulfillment Of The 
Requirement For The Degree of Master Of Medicine (Surgery) 
 
 
UNIVERSITI SAINS MALAYSIA 
2018 
ii 
 
ACKNOWLEDGEMENTS 
 
I would like to wish my gratitude to Allah the Almighty for the chance and opportunity 
given to partake in this thesis and the Masters of Medicine program. 
I would also wish to express my gratitude to my course supervisor, Dr. Maya Mazuwin 
for her input and guidance in completing this thesis. I would like to also express my appreciation 
for Dato Dr. Azhar Amir Hamzah and Dr. Mohd Nor Gohar for their expert input and guidance. 
Also, I would like to thank the head of Surgery Department, Prof Madya Dr. Zaidi 
Zakaria for his input and words of encouragement. 
Last but not least, I would like to thank my wife and family members for their 
unwavering support.   
 
 
 
 
 
 
 
 
 
iii 
 
TABLE OF CONTENTS 
PAGE 
ACKNOWLEDGEMENT         ii 
TABLE OF CONTENT         iii 
ABSTRACT           iv 
ABSTRAK           vi 
1.0 INTRODUCTION 
1.1 INTRODUCTION        1  
1.2 LITERATURE REVIEW       1  
1.3 RATIONALE OF STUDY       10 
2.0 STUDY PROTOCOL 
2.1 DOCUMENTS SUBMITTED FOR ETHICAL APPROVAL  11 
2.2 HUMAN RESEARCH AND ETHICS COMMITTEE APPROVAL  38 
3.0 BODY 
3.1 TITLE PAGE         41 
3.2 ABSTRACT         42 
3.3 INTRODUCTION        44 
3.4 METHODOLOGY        44 
3.5 RESULTS         48 
3.6 DISCUSSION         74 
3.7 REFERENCES         85 
4.0 APPENDICES          90 
iv 
 
ABSTRACT 
 
Background 
Testicular cancer is a rare malignancy worldwide, especially among Asians. Even though it is 
associated with 98% survival, it is mainly a disease of young adults and the incidence is 
increasing worldwide. There is no reported survival outcome among testicular cancer patients 
who are treated in Hospital Universiti Sains Malaysia (HUSM), Kubang Kerian. This study aims 
to analyze the 5-years OS and PFS and associated predictive factor for survival among testicular 
cancer patients treated in HUSM. 
Methodology 
This is a retrospective cohort study performed in HUSM. All histopathology confirmed cases of 
testicular cancer are included. Patient demographics, histopathological findings of the surgical 
specimen, serum tumor markers, relevant radiological findings, treatment modalities received 
and patient survival status until 31st July 2017 were reviewed. Kaplan-Meier plot was used to 
calculate 5-years OS and PFS. Log-rank test and Pairwise comparison were used to calculate the 
survival difference between two or more groups. Univariate Cox regression analysis was used to 
analyze the association between predictive factors and survival outcome.  
Results 
Sixty-two (62) patients were included in the study with a median follow-up of 20.5 months. 
Median age at diagnosis is 33 years and 95% of patients are from Malay ethnic group. Non-
seminomatous Germ-cell tumor (NSGCT) is the most common tumor subgroup comprising 
66.1%. More than 65% of patients presented with metastatic disease at presentation. Five-year 
OS is 68.4%, 64.2% and 33.3% for NSGCT, seminoma and non-germ cell tumor (NGCT) 
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respectively. Five-year PFS is 51.0%, 41.0% and 26.7% for NSGCT, seminoma and NGCT 
respectively. Co-existing Diabetes/ hypertension (HR= 3.72, 95% CI: 1.52 – 9.11; p= 0.004), 
Non-germ cell histology (HR= 4.11, 95% CI: 1.52 – 11.14; p= 0.005) and presence of spermatic 
cord invasion (HR= 3.30, 95% CI: 1.12 – 9.77; p=0.031) are associated with poor OS. Age group 
51 to 60 years is the only predictive factor for poorer OS (HR= 9.65, 95% CI: 2.05 – 45.5; p= 
0.004) and PFS (HR= 10.25, 95% CI: 2.29 – 45.9; p= 0.002).  
Conclusion 
Testicular cancer is a rare disease which mainly affects young Malay males. NSGCT is the 
commonest subtype encountered and is associated with the highest OS and PFS. Age 51 to 60 is 
associated with worse OS and PFS. Meanwhile, co-existing Diabetes or hypertension, non-Germ 
cell histology, and presence of spermatic cord invasion are predictors of poor OS.  
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ABSTRAK 
 
Latar Belakang 
Kanser testis adalah kanser yang jarang berlaku terutamanya dalam kalangan penduduk Asia. 
Kanser tersebut dikaitkan dengan kelangsungan hidup yang tinggi tetapi kerap berlaku dalam 
golongan muda. Insiden kanser testis juga kian meningkat di seluruh dunia. Tidak ada kajian 
yang melaporkan berkaitan kelangsungan hidup pesakit-pesakit kanser testis yang dirawat di 
Hospital Universiti Sains Malaysia (HUSM), Kubang Kerian. Kajian ini bertujuan untuk 
menganalisa “Kadar Kelangsungan Hidup (OS)” dan “Kadar Kelangsungan Hidup Bebas 
Penyakit (PFS)” bagi tempoh 5 tahun serta faktor-faktor yang meramal kelangsungan hidup 
dalam kalangan pesakit kanser testis. 
Metodologi 
Kajian kohort secara retrospektif ini dijalankan di HUSM dan telah mengkaji semua kes kanser 
testis yang telah disahkan melaui pemeriksaan histo-patologi. Maklumat yang diteliti adalah 
termasuk demografi pesakit, penemuan histopatologi spesimen pembedahan, aras serum penanda 
tumor, penemuan radiologi yang relevan, modaliti rawatan yang diterima dan status 
kelangsungan pesakit sehingga 31 Julai 2017. Plot Kaplan-Meier digunakan untuk menghitung 
OS dan PFS 5-tahun. Ujian “Log-rank” dan “Pairwise comparison” diguna pakai untuk 
menganggar perbezaan kelangsungan di antara dua atau lebih kumpulan. Kaedah regresi Cox 
digunakan untuk menganalisa hubungan antara faktor peramal dan kelangsungan hidup. 
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Keputusan 
Enam puluh dua (62) pesakit telah dikaji dan menerima rawatan susulan bagi tempoh median 
20.5 bulan. Umur median pesakit ketika didiagnosa kanser adalah 33 tahun. 95% daripada 
pesakit merupakan daripada kumpulan etnik Melayu. Tumor “Non-seminomatous Germ cell” 
(NSGCT) adalah jenis tumor yang paling kerap dihadapi. Manakala 65% daripada pesakit telah 
didiagnosa dengan penyakit peringkat metastatik. Kadar OS 5-tahun adalah 68.4%, 64.2% dan 
33.3% untuk tumor NSGCT, seminoma dan tumor “non-germ cell” (NGCT). PFS 5 tahun pula 
adalah 51.0% untuk NSGCT, 41.0% untuk seminoma dan 26.7% untuk NGCT. Penyakit 
Diabetes mellitus/ darah tinggi (HR = 3.72, 95% CI: 1.52 - 9.11; p= 0.004), histologi “Non-germ 
cell” (HR= 4.11, 95% CI: 1.52 – 11.14; p= 0.005), dan penglibatan salur spermatik (HR = 3.30, 
95% CI: 1.12 - 9.77: p= 0.031) dikaitkan dengan OS yang rendah. Kumpulan umur 51 hingga 60 
tahun adalah satu-satunya faktor ramalan bagi kedua-dua OS (HR = 9.65, 95% CI: 2.05 - 45.5; 
p= 0.004) dan PFS yang rendah (HR= 10.25, 95% CI: 2.29 – 45.9; p= 0.002). 
Kesimpulan 
Kanser testis adalah penyakit yang jarang dihadapi tetapi memberi kesan terutamanya kepada 
lelaki Melayu muda. NSGCT adalah jenis yang paling kerap yang dihadapi dan menunjukkan 
kadar kelangsungan paling tinggi dalam kalangan penghidap kanser testis. Pesakit berumur 51 
hingga 60 dikaitkan dengan kedua-dua OS and PFS yang lebih rendah. Sementara itu, pesakit 
Diabetes atau darah tinggi, histologi jenis “Non-germ cell” dan penglibatan salur spermatik akan 
meramal OS yang lebih rendah.
1.1 INTRODUCTION 
Testicular cancer is a rare urology malignancy that affects 0.4% of all men (National 
Cancer Institute, 2016) and comprises 1% of all newly diagnosed malignancy in adults. 
Incidence of testicular cancer in Asians are reported 0.7 to 1.3 per 100,000 population. Incidence 
of testicular cancer is highest among Scandinavian which is reported around 2.9 to 10.3 per 
100,000 population (Garner et al., 2005; Manecksha & Fitzpatrick, 2009). Interestingly, most of 
testicular cancers are diagnosed in patients in the prime age of 35 years old or younger. 5-year 
Overall Survival is excellent ranging from 95 to 98% and mortality from testicular cancers are 
rare (Garner et al., 2005; Omar & Tamin, 2011; Australian Institute of Health and Welfare, 
2014; Cancer Research UK, 2016; National Cancer Institute, 2016).  
1.1 LITERATURE REVIEW 
1.1.1 Histopathological Types: Primary testicular cancers are classified according to World 
Health Organization classification into Germ Cell (GCT) and Non – Germ Cell Tumor (NGCT). 
GCTs are more common with a frequency of 80%. It can further be sub-divided to seminoma 
and non-seminoma. On the other hand, NGCTs includes sex cord cells tumors, carcinoid tumors, 
tumors of ovarian epithelial type, hematopoietic tumors, and mesenchymal tumors of spermatic 
cord or para-testicular tissues. Testicular cancers may present as pure single histology type or 
mixed histology subtypes (Sesterhann & Davis, 2004; Eble et al., 2004; Chalya et al., 2014).  
1.1.2 Presenting Symptoms: Patient commonly presents with the complaint of unilateral 
painless testicular swelling. Other common symptoms at presentation include scrotal heaviness, 
testicular pain, abdominal swelling and primary infertility. (Thornhill et al., 1986; Khan & 
Protheroe, 2007; Chalya et al., 2014).  
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1.1.3 Risk Factors: Previous observational studies have identified certain risk factors for the 
development of testicular cancer:  
1) Cryptorchidism/ mal-descent testis: Patients with cryptorchidism are 7 to 9 times more 
likely to be diagnosed with testicular cancer (Pinczowski et al., 1991; Moller & 
Skakkebæk, 1996; Swerdlow et al., 1997) 
2) Testicular carcinoma in-situ: Skakkebæk et al. (1972) observed patients with atypical 
germ cell neoplasia during testicular biopsy for infertility and who was later diagnosed 
with testicular carcinoma 
3) Sub-fertility: A man with children is 40% less likely to be diagnosed with testicular 
cancer compared to a man without child (Møller & Skakkebaek, 1999; Jacobsen et al., 
2000) 
4) Previous history of testicular malignancy: Patients with testicular cancer are 22 to 27 
times more likely to develop a second primary testicular cancer in the contralateral testis 
(Osterlind et al., 1991; Colls et al., 1996; Che et al., 2002) 
5) Paternal or siblings with testicular cancer: Twins to a patient with testicular cancer is 37 
times more likely to be diagnosed with testicular cancer. The increase in incidence also 
observed among non-twin brothers (8 to 9 times increased in relative risk) and an 
offspring to a father with testicular cancer (4 times increase risk) (Forman et al., 1992; 
Swerdlow et al., 1999; Chalya et al., 2014).  
1.1.4 Prognostic Factors: Factors which are identified contributing to poor patient outcome 
include presence of tumor larger than 4 cm, tumor invasion of rete testis (Warde et al., 2002), 
presence of lympho-vascular invasion, embryonal histology and trans-scrotal involvement Commented [G6]: Deleted:- 
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(Nicolai & Pizzocaro, 1995; Colls et al., 1999; International Prognostic Factors Study Group, 
2010). 
1.1.5 Role of Ultrasonography of Testis: Ultrasonography of both testes is the first choice of 
imaging modality in suspected testicular cancer. Ultrasonography is safe, radiation-free and is 
widely available. It is a relatively inexpensive modality to accurately differentiate between intra- 
and extra-testicular mass, vascularity, synchronous tumor of the contralateral testis and identify 
different tumor subtypes (Lung & Sidhu, 2011; Kreydin et al., 2013). 
1.1.6 Role of Tumor Markers: Tumor markers for testicular cancers are readily available and 
proven for diagnosis and management of GCTs since the 1980s (Light, 1985). Tumor markers 
are used to diagnose, stage, prognosticate, decide adjuvant therapy, monitor response to 
treatment and monitor for recurrence (Light, 1985; Leman & Gonzalgo, 2010; Milose et al., 
2012; Fizazi et al., 2015). Baseline tumor markers should be obtained prior to orchidectomy and 
repeated until tumor markers normalize. Elevated tumor markers are directly proportionate to 
tumor burden (Milose et al., 2012). Persistently elevated tumor markers after surgery suggest the 
presence of residual disease or metastases. 
1) Alpha-fetoprotein (AFP): AFP is a glycoprotein molecule which is synthesized in the 
fetal yolk sac, liver and intestine. Half-life of AFP is 5 to 7 days. It is raised in 
embryonal, teratoma and yolk sac tumors. AFP is not produced in pure seminoma or 
choriocarcinoma (Light, 1985; Milose et al., 2012). 
2) β-Human Chorionic Gonadotrophin (β-HCG): β-HCG is a glycoprotein molecule 
composed of an α and a β-subunit. β-HCG is produced by syncytiotrophoblast giant cells. 
Half-life of β-HCG is 24 to 36 hours. This tumor marker is raised in seminoma, 
choriocarcinoma and embryonal tumors (Light, 1985; Milose et al., 2012) 
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3) Lactate dehydrogenase (LDH): LDH is a cellular enzyme normally produced in muscle 
cells, kidney, brain and liver. There are multiple LDH iso-enzymes with variable half-
life. LDH is elevated in up to 40-60% of testicular GCTs and levels more than 2000 U/L 
is suggestive of bulky disease (Milose et al., 2012). 
1.1.7 Disease Staging: The American Joint Committee on Cancer (AJCC) TNM staging is used 
to define the extent and spread testicular cancer to lymph nodes and distant organs. Staging of 
cancer helps to decide appropriate treatment based on collective outcomes of similar groups 
(AJCC, 2010). The International Germ Cell Cancer Collaborative Group (IGCCCG) prognosis 
system is used to classify metastatic GCTs (Mead, 1997). Newer prognosticating models has 
been developed to identify specific poor prognosis groups which may not respond to standard 
chemotherapy (Bhala et al., 2004; Fizazi et al., 2004; Sammler et al., 2008; International 
Prognostic Factors Study Group, 2010; Kojima et al., 2015). 
 
TNM staging for testicular cancer adapted from AJCC TNM 7th Edition 
Primary Tumor 
pTx 
pT0 
pTis 
pT1 
 
pT2 
 
pT3 
pT4 
 
Primary tumor cannot be assessed. 
No evidence of primary tumor. 
Intratubular germ cell neoplasia (testicular intraepithelial neoplasia). 
Tumor limited to testis and epididymis without vascular/ lymphatic invasion. 
Tumor may invade tunica albuginea but not tunica vaginalis. 
Tumor limited to testis with vascular/ lymphatic invasion. OR tumor extending 
through tunica albuginea with involvement of tunica vaginalis. 
Tumor invades spermatic cord with/ without vascular invasion. 
Tumor invades scrotum with/ without vascular invasion. 
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Regional lymph nodes 
Nx 
N0 
N1 
 
N2 
 
 
N3 
 
Regional lymph nodes cannot be assessed 
No regional lymph nodes metastases 
Metastases with a lymph node mass 2 cm or less in greatest diameter, OR multiple 
lymph nodes, none more than 2cm in diameter 
Metastases with a lymph node mass more than 2cm but not more than 5cm in 
diameter, Or multiple lymph nodes, any one mass more than 2 cm but not more 
than 5 cm in diameter. 
Metastases with a lymph node larger than 5 cm in diameter. 
Distant metastases 
Mx 
M0 
M1a 
M1b 
 
Distant metastases cannot be assessed 
No distant metastases 
Distant metastases to non-regional lymph node or lungs 
Distant metastases to other site(s) 
Serum tumor markers 
Sx 
S0 
 
S1 
S2 
S3 
 
Serum tumor markers not available/ not performed 
Serum tumor marker within normal limits 
AFP (ng/ml) Β-HCG (mIU/ml) LDH (U/L) 
<1000 <5000 <1.5 x Normal 
1000 - 10000 5000 - 50000 1.5 – 10 x Normal 
>10000 >50000 >10 x Normal 
 
Stage 
Stage I 
   IA 
   IB 
   IS 
Stage II 
 
Any pT N0 M0 Sx 
pT1 N0 M0 S0 
pT2-4 N0 M0 S0 
Any pT N0 M0 S1-3 
Any pT N1-3 M0 Sx 
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   IIA 
   IIB 
   IIC 
Stage III 
   IIIA 
   IIIB 
   IIIC 
Any pT N1 M0 S0 OR Any pT N1 M0 S1 
Any pT N2 M0 S0 OR Any pT N2 M0 S1 
Any pT N3 M0 S0 OR Any pT N3 M0 S1 
Any pT Any N M1 Sx 
Any pT Any N M1a S0 OR Any pT Any N M1a S1 
Any pT N1-3 M0 S2 OR Any pT Any N M1a S2 
Any pT N1-3 M0 S3 OR Any pT Any N M1a S3 OR Any pT Any N M1b Any S  
 
1.1.8 Treatment options 
1.1.8.1 High orchidectomy: All patient with suspected testicular cancer should undergo radical 
high orchidectomy via an inguinal exploration. A skin incision is made in the inguinal region 3 
cm above the inguinal skin fold and the subcutaneous fascia divided. The spermatic cord is 
isolated at the external inguinal ring using blunt dissection, the testis within the tunica is 
separated from the scrotum. The testis is free to be examined after division of the gubernaculum. 
After the surgeon confirms the presence of testicular tumor, the external oblique aponeurosis is 
divided until exposing the internal inguinal ring. The spermatic cord is clamped as high as 
possible and the spermatic cord structures are individually ligated. After the cord is divided, care 
is taken to avoid tumor spillage. The wound is washed with distilled water for irrigation and the 
surgical layers are closed in layers (Pizzocaro & Guarneri, 2009). Testis-sparing surgery is a safe 
alternative and may be considered in patients with synchronous bilateral tumor, metachronous 
contralateral tumor or tumor smaller than 30% of the testicular volume (Weissbach, 1995; 
Brunocilla et al., 2013). Intraoperative frozen section is also an option if there is doubt regarding 
the testicular mass prior to radical orchidectomy. Trans- scrotal biopsy is contraindicated in 
suspected testicular cancer. 
Commented [G9]: Inserted: an  
Commented [G10]: Inserted: e th 
Commented [G11]: Inserted: the  
7 
 
1.1.8.2 Retroperitoneal Lymph Node Dissection (RPLND): RPLND was classically indicated 
in all testicular cancers patient for staging lymph node metastases and surgical cure of 
retroperitoneal disease. Nerve sparing techniques was introduced to improve the morbidity of 
RPLND complications including erectile dysfunction. Current techniques involve the use of 
laparoscopic or robotic nerve sparing RPLND and is indicated for residual retroperitoneal tumor 
post chemotherapy (Ranieri et al., 1994; Klein, 2000; Nonomura et al., 2002; Mitsinikos et al., 
2012; Hillelsohn et al., 2012; Hugen et al., 2016).   
1.1.8.3 Chemotherapy: Platinum-containing chemotherapy has played an important role in the 
management of testicular GCTs. Einhorn (1977) reported 85% cure rate in treating metastatic 
testicular cancer with Cisplatin-Vinblastine-Bleomycin (PVB) regime. Substitution of 
Vinblastine with Etoposide shows improved survival with a better toxicity profile. This has led 
to the Bleomycin-Etoposide-Cisplatin (BEP) regime which is the standard first line 
chemotherapy regime in the management of Stage II and III testicular GCTs (Peckham et al., 
1983; Williams et al., 1987). Patients who receive BEP chemotherapy has shown complete cure 
rates up to 95% and 90% 5-year survival (Mead, 1997).  
Study by Einhorn et al (1989) found that among metastatic testicular cancers with 
IGCCCG favorable prognosis group, 3 cycles of BEP chemotherapy is the optimum duration. 
Intermediate and poor prognosis metastatic GCTs are given an extra cycle of BEP regime 
(Einhorn et al., 1989; Einhorn, 2006). Cisplatin-based chemotherapy has been associated with 
severe oto-, neuro- and nephro-toxicity. A study in Germany showed that substituting cisplatin 
for Carboplatin (JEB) regime having comparable response rate to BEP (Pinkerton et al., 1990; 
Bokemeyer et al., 1996). However, there is a significant risk of late relapse (32% vs 13%, p= 
0.03). Another identified complication of Bleomycin is the risk of pulmonary toxicity. A study 
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by de Wit et al. (1997) has shown that patients who receive Etoposide-Cisplatin (EP) regime are 
less likely to achieve complete pathological response compared to patients who receive BEP 
(87% vs 95%, p= 0.0075). However, both groups show similar Overall Survival and Disease 
Free Progression (de Wit et al., 1997). Attempts to improve the standard chemotherapy regime 
was largely unsuccessful. The addition of Paclitaxel to BEP (BEP-T) shows higher 
complications but did not show survival benefit (de Wit et al., 2012). Substitution of Bleomycin 
with Ifosfamide in Cisplatin-Ifosfamide-Etoposide (VIP) had higher rates of toxic complications 
compared to BEP. VIP and other regimes containing Ifosfamide and/ or Paclitaxel are used as 
second and third-line chemotherapy or for salvage chemotherapy in recurrent metastatic 
testicular cancers (Loehrer et al., 1986; Nichols et al., 1998; Motzer et al., 2000; Kondagunta et 
al., 2005). High-dose chemotherapy (HDCT) with autologous stem cell rescue offers up to 27% 
cure among patients with metastatic testicular GCTs refractory to second or third line 
chemotherapy (Einhorn et al., 2007). However, HDCT is associated with high toxicity rates and 
morbidities. Fizazi et al. (2015) studied into intensification of chemotherapy dosage among 
patient who did not show immediate response by monitoring serial tumor marker decline rates. 
Patient who were subjected to dose intense chemotherapy shows improved PFS and is more 
likely to avoid HDCT compared to patients who receive standard dose chemotherapy (Fizazi et 
al., 2015).  
1.1.8.4 Radiotherapy (RT): Adjuvant RT reduces the relapse rate for Stage I seminomatous 
GCT from 14% to 4% compared to patients undergoing active surveillance alone. However, 
patients who received adjuvant RT are 2 times more likely to have a second malignancy in the 
contralateral testis compared with patients who undergo orchidectomy alone (Travis et al., 
2005). Alternatively, Carboplatin 7 Area Under the Curve (AUC) achieved similar reduction in 
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risk of testicular cancer relapse in Stage I seminoma and 80% less likely of developing a second 
malignancy in the contralateral testis (Oliver et al., 2011).  
1.1.9 Local Studies: In Malaysia, an average of 19000 newly diagnosed cancer cases was 
reported annually in 2006 and 2007 with men comprising 45% of the cases. Testicular cancers 
make up 1% of all newly diagnosed malignancies in Malaysian men. In 2006, 104 new cases of 
testicular cancer were reported and another 74 new cases were reported the following year. The 
commonest ethnic group diagnosed with testicular cancer is the Malay ethnic group (n=99), 
followed by Chinese (n=46) and Indian (n=11). 75% of testicular cancer cases were diagnosed 
among 15 to 50-years of age. Seminoma (35%) was the commonest single histology tumor 
subtype in 2007 (National Cancer Registry, 2006; Omar & Tamin, 2011). 
Tan et al. (2011) reported similar Malay ethnic predominance from their 10-years 
retrospective study based in a tertiary center in the national capital of Kuala Lumpur. The author 
reported 33 cases of testicular cancers treated in the study period with 87% comprised of GCTs. 
However, in their series, they encountered more NSGCTs (n=21) compared to seminomas (n=6). 
NSGCTs were diagnosed with a mean age of 28.7 years where as seminoma was diagnosed at a 
mean age of 31.3 years. Cases of primary testicular lymphomas were diagnosed among older 
patients with mean age of 69.7 years. Seventy percent of GCTs presented with raised serum 
tumor markers either AFP, β-HCG or LDH. All cases of testicular lymphoma presented with 
raised LDH. The single case of rhabdomyosarcoma of testis was negative for all three serum 
tumor markers. All of the patients had high radical orchidectomy and majority of them received 
adjuvant chemotherapy. The authors reported 5-year OS of 83.9% in their series. However, the 
authors did not elaborate regarding patient stage at diagnosis, prognostic factors, chemotherapy 
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regimes used, the response of the tumor to the chemotherapy, salvage treatment offered, 
complications after treatment and duration of follow up (Tan et al., 2011).   
 
1.2 RATIONALE OF STUDY 
This study aims to bridge the lack of local data on the testicular cancer cohort. This retrospective 
cohort study intends to identify patients’ demographics, common presenting symptoms, clinical-
pathological characteristics, 5-year OS and PFS. This study was planned to identify whether 
factors such as age at presentation, co-existing morbidities, site of primary tumor, histology 
subtype, presence of lympho-vascular invasion, presence of spermatic cord invasion, site of 
tumor metastases and disease staging at diagnosis are associated with patient outcome (OS and 
PFS). This study was also designed to study the types of treatment modalities given and to 
identify common complications of treatment. This study may identify specific target population 
factors which may contribute to the local testicular cancer patient survival and act as a reference 
for future audits. 
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2. STUDY PROTOCOL 
2.1 DOCUMENTS SUBMITTED FOR ETHICAL APPROVAL 
 
STUDY PROTOCOL PROPOSAL 
REVIEW OF TESTICULAR CANCER FROM 2000 TO 2015 IN HUSM 
Principal Researcher: 
Dr. Ahmad Khairil Irham bin Harun (P-UM0170/14) 
MPM 48008 
Supervisor: 
Dr. Maya Mazuwin Yahya (1390/08) 
MPM 37639 
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INTRODUCTION 
Testicular cancer is a rare malignancy that affects approximately 0.4% of all men (National 
Cancer Institute, 2016) with a reported incidence of 1% of newly diagnosed malignancy in 
adults. Most testicular cancers are diagnosed in patients younger than 35 years old. 5-year 
Overall Survival has been reported excellent ranging from 95 to 98% and mortality from the 
disease is rare (Garner et al., 2005; Omar & Tamin, 2011; Australian Institute of Health and 
Welfare, 2014; Cancer Research UK, 2016; National Cancer Institute, 2016).  
 Testicular cancer can be classified according to Germ Cell (GCT) and Non – Germ Cell 
Tumor (NGCT). GCTs are the commoner of the two with a frequency of 80%. GCTs as the 
name implies originates from germ cell and can be sub-classified to seminoma and non-
seminoma. On the other hand, NGCT may arise from sex cord cells, hematological, epithelial or 
mesenchymal origin. Testicular cancer also presents with mixed histology subtypes (Eble et al., 
2004; Sesterhenn & Davis, 2004; Chalya et al., 2014).  
  Patient most commonly presents with a complaint of unilateral painless testicular 
swelling. Other common symptom at presentation includes scrotal heaviness and testicular pain 
(Thornhill et al., 1986; Khan & Protheroe, 2007; Chalya et al., 2014).  
 Previous studies have identified certain risk factors for developing testicular cancer: 
cryptorchidism ( Pinczowski et al., 1991; Moller & Skakkebæk, 1996; Swerdlow et al., 1997), 
testicular carcinoma in-situ (Skakkebæk, 1972; Moller & Skakkebæk, 1996; Rørth et al., 2000), 
sub-fertile men (Møller & Skakkebaek, 1999; Jacobsen et al., 2000), previous history of 
testicular malignancy (Osterlind et al., 1991; Colls et al., 1996; Che et al., 2002), paternal or 
siblings with testicular cancer (Forman et al., 1992; Chalya et al., 2014). Factors which are 
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identified as poor prognostic factors include presence of tumor sized more than 4 cm, invasion of 
rete testis (Warde et al., 2002), presence of lymphovascular invasion, embryonal histology and 
trans-scrotal involvement ( Nicolai & Pizzocaro, 1995; Colls et al., 1999; International 
Prognostic Factors Study Group, 2010). 
 Once testicular cancer is clinically suspected, ultrasonography of both testes will be done 
along with serum tumor markers (α-Fetoprotein, β-Human Chorionic Gonadotrophin, and 
Lactate dehydrogenase). Ultrasonography of the testes is widely available and it is a relatively 
inexpensive modality to accurately differentiate between intra- and extra-testicular mass, 
vascularity, a synchronous tumor of the contralateral testis and differentiate tumor subtypes 
(Lung & Sidhu, 2011; Kreydin et al., 2013). 
 Testicular cancers are surgically approached via an inguinal incision, the testis is 
exteriorized within its intact tunica layer and the spermatic cord ligated and transected at the 
deep inguinal ring. A prosthesis may be placed into the scrotum in the same surgical setting. 
Once the histopathological diagnosis is confirmed, patients will undergo further imaging studies 
to complete clinical staging. The American Joint Committee on Cancer (AJCC) TNM staging is 
commonly used to define the extent and spread of the tumor to lymph nodes and distant organs. 
Staging of cancer helps in decision making on appropriate treatment based on collective 
outcomes of similar groups (AJCC, 2010). The International Germ Cell Cancer Collaborative 
Group (IGCCCG) is also a widely used prognostic system specifically for metastatic GCTs 
(Mead, 1997). Newer prognosticating models has been developed and proposed by multiple 
researchers to identify poor prognosis groups which may not respond to standard therapy (Bhala 
et al., 2004; Fizazi et al., 2004; Sammler et al., 2008; International Prognostic Factors Study 
Group, 2010; Kojima et al., 2015).  
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 Platinum-containing chemotherapy played a tremendous role in the management of 
metastatic testicular GCTs. Einhorn reported 85% cure rate in treating metastatic testicular 
cancer with Cisplatin-Vinblastine-Bleomycin (PVB) regime (Einhorn, 1977). Substitution of 
Vinblastine with Etoposide has shown improved survival with a better toxicity profile. This leads 
to the Bleomycin-Etoposide-Cisplatin (BEP) regime which is even currently used as first line 
chemotherapy (Peckham et al., 1983; Williams et al., 1987). Among metastatic GCTs, the patient 
achieved up to 90% cure rate and survival (Mead, 1997). The chemotherapy duration was 
optimized to 3 cycles for good prognosis in metastatic testicular cancer to reduce toxic 
complications (Einhorn et al., 1989; Einhorn, 2006).  
Bleomycin carries the risk of pulmonary toxicity. However, chemotherapy regimes which 
attempted to exclude Bleomycin shows less favorable outcome (de Wit et al., 1997). Attempts to 
improve the standard chemotherapy regime was largely unsuccessful. The addition of Paclitaxel 
to BEP (BEP-T) do not show any survival benefit (de Wit et al., 2012). Meanwhile, substitution 
of Bleomycin with Ifosfamide in Cisplatin-Ifosfamide-Etoposide (VIP) has higher toxic 
complications compared to BEP. VIP and other regimes containing Ifosfamide and/ or Paclitaxel 
are used as second-line chemotherapy or for salvage therapy in recurrent metastatic testicular 
cancers (Loehrer et al., 1986; Nichols et al., 1998; Motzer et al., 2000; Kondagunta et al., 2005). 
High-dose chemotherapy (HDCT) with autologous stem cell rescue offers up to 27% cure among 
patients not responsive to second or third line chemotherapy (Einhorn et al., 2007). However, 
HDCT is recommended for refractive metastatic testicular GCTs is due to higher toxicity and 
morbidities. The latest study into chemotherapy agent intensification may avoid poor prognosis 
patients undergo HDCT. A patient who received dose-dense chemotherapy has better PFS and 
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lower risk for requiring salvage HDCT compared to patients on standard dose chemotherapy 
(Fizazi et al., 2015). 
In Malaysia, an average of 19000 newly diagnosed cancer cases was reported annually in 
2006 and 2007 with men comprising 45% of the cases. The incidence of testicular cancer among 
Malaysian men comprises 1% of all newly diagnosed cases. 104 new cases of testicular cancer 
were reported in 2006 and another 74 new cases were reported the following year.  
The commonest ethnic group diagnosed with testicular cancer is the Malay ethnic group 
(n=99), followed by Chinese (n=46) and Indian (n=11).  Almost 75% of cases are diagnosed 
among 15 to 50-years of age. The commonest single histology tumor subtype reported in 2007 
was seminoma (35%).  (National Cancer Registry, 2006; Omar & Tamin, 2011).  
Tan et al. (2011) reported similar Malay ethnic predominance and relatively young mean 
age at diagnosis. However, in their series, they encountered more NSGCTs compared to 
seminomas. The authors reported 5-year OS of 83.9% which is lower compared to larger 
published series. However, they did not elaborate regarding patient stage at diagnosis, prognostic 
factors, chemotherapy regimes used, the response of the patient to the treatment and whether any 
salvage treatment was offered (Tan et al., 2011).   
This study aims to bridge this lack of local data on the local testicular cancer cohort. This 
retrospective review intends to identify local patients’ demographics, the proportions of different 
histological testicular cancer subtypes and 5-year OS. We also plan to identify individual risk 
factors and prognostic factors which may contribute to a patient’s outcome. The study is also 
designed to collect the frequency of different treatment modalities offered to patients and the 
frequency of complications. This study may identify specific target population factors which 
Commented [G55]: Deleted:ere 
Commented [G51]: Inserted: as 
Commented [G56]: Deleted:I 
Commented [G52]: Inserted: The i 
Commented [G53]: Inserted:  the 
Commented [G54]: Inserted: the  
Commented [G57]: Inserted:  the 
16 
 
may contribute to these patients’ outcome and act as a reference for future audits.
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RESEARCH QUESTIONS 
1. What is the prevalence of testicular cancer in HUSM from 2000 until 2015? 
2. What are the demographics and commonest presentation of testicular cancer? 
3. What is the most common histological subtype of testicular cancer encountered in 
HUSM? 
4. What is the most common stage at diagnosis of testicular cancer presented in HUSM? 
5. What is the Overall Survival and Progression Free Survival for these patients?  
6. Is there an association between prognostic factors (age, duration of symptoms, site of 
cancer, histological subtype, lymphovascular invasion, the size of primary tumor, 
spermatic cord involvement, site of metastases, staging of the primary tumor and co-
morbids) with Overall Survival and Progression-Free Survival? 
7. What is the commonest chemotherapy regime used in HUSM for the treatment of 
testicular cancer?  
8. What is the frequency of complications of chemotherapy? 
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OBJECTIVE 
• General objective 
 To study the prevalence, outcome and possible prognostic factors among patients 
diagnosed with testicular cancer in HUSM 
• Specific objectives 
 To describe the demographics of testicular cancer patients treated in HUSM from 
2000 until 2015 
 To identify the commonest presentation of patients diagnosed with testicular 
cancer in HUSM 
 To describe the proportions of different histology subtypes and staging at 
diagnosis of testicular cancer patients presented in HUSM 
 To calculate the Overall Survival and Progression Free Survival for testicular 
cancer patients in HUSM 
 To identify the association between prognostic factors and patients’ outcome 
(Progression Free Survival and Overall Survival) 
 To describe the proportions of chemotherapy regimes in the management of 
testicular cancer in HUSM 
 To describe the proportions of complications of chemotherapy 
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METHODOLOGY 
Research Design 
This study is a retrospective cohort study involving patients diagnosed with testicular cancer in 
HUSM. 
Study Area 
Data collection will be done in HUSM. 
Source Population 
- Reference population 
o Testicular cancer patients attended in HUSM 
- Target population 
o Testicular cancer patients treated in HUSM from 1st January 2000 until 31st 
December 2015 
- Sampling frame 
o HUSM admission register for testicular cancer 
Subject Criteria 
- Inclusion criteria 
o Patients with histopathological (HPE) confirmed diagnosis of testicular cancer 
o Patients treated in HUSM during the study period 
- Exclusion criteria 
o Incomplete or missing case notes 
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o Patients diagnosed with testicular cancer and other concomitant malignancy 
Sampling Method 
Convenience sampling. Case folders will be traced from HUSM record unit until the calculated 
sample size is achieved. 
Sample Size 
Median survival time in control group formula (m1) 
m1= t log e (1/2)/ log e (p) 
p   = probability of subject survives until time (t) 
Tan GH et al (2011) reported 84% 5-years survival. Thus, 
m1 = 60 log e (1/2)/ log e (0.84) = 36 months 
Median survival time in experimental group (m2) 
de Wit et al (1997) reported 89% 3-years survival 
m2 = 36 log e (1/2)/ log e (0.89) = 20 months 
Sample size calculations via PS Power and Sample Size Calculation Software Version 3.0. 
Parameters Value 
α 0.05 
Power 0.8 
Median survival time 1 (m1) 36 
Median survival time 2 (m2) 20 
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Accrual time in which patients are recruited (months) 180 
Additional follow up time after end of recruitment (months) 60 
Ratio of control to experiment 1 
 
Sample size required with 10% drop out is 60 patients. 
Data Collection 
Information collected from case notes will be filled in written or electronic data collection sheet. 
Definition of Terms Employed in this Study 
 “Overall Survival” is defined as the length of time from the start of treatment or the date 
of diagnosis for a disease, such as cancer, that patients diagnosed with the disease are still 
alive. Usually expressed as 5-year Overall Survival. The date of starting primary 
chemotherapy is taken as the date of starting treatment (National Cancer Institute). 
 “Progression Free Survival” is defined as the length of time during and after the treatment 
of a disease, such as cancer, that a patient lives with the disease but it does not get worse. 
Measured from the start of primary chemotherapy until the onset of disease progression 
(biochemical/ radiological relapse, disease progression or death) (National Cancer 
Institute). 
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Data Analysis 
Data will be entered and analyzed using SPSS version 22. Descriptive statistics will be used to 
summarize the socio-demographic characteristics of subjects. Numerical data will be presented 
as mean (Standard Deviation) or median (Inter-Quartile Range) based on their normality 
distribution. Categorical data will be presented as frequency and percentage. 
Kaplan-Meier plot or Life Table Method will be used to calculate mean and median 
Overall Survival and Progression Free Survival.  
Association between prognostic factors and survival will be analyzed with Simple Cox 
Regression.   
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Flow Chart 
Thesis proposal ethical clearance 
 
Formulation of patient list (sample population) from Records Unit 
 
Tracing patient records 
 
Data collection into written/ electronic data collection sheet 
 
Data compiled and entered into SPSS 
 
Statistical analysis 
 
Report and manuscript write up 
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Milestones 
- Ethical approval by 31 March 2017 
- Data collection by 31 May 2017 
Data analysis and manuscript writing by 31 Jun 2017 
